#China #Shanghai #biopharmaceuticals #Harbour BioMed #antibody therapeutics

Introduction

On March 30, 2026, Harbour BioMed (HBM), a prominent global biopharmaceutical firm, revealed its financial performance for the fiscal year ending December 31, 2025. This year marked a transformative phase for the Company with a strong commitment to innovation and collaborations that lay the groundwork for long-term growth in the fields of immunology, oncology, and more.

Strategic Growth

Dr. Jingsong Wang, the founder, Chairman, and CEO of Harbour BioMed, emphasized that 2025 was a key year in the company's strategic evolution, as they worked towards their vision for 2028 to establish HBM as a leading biopharmaceutical group. The organization focuses on three main growth engines: constructing a cutting-edge AI-driven antibody discovery infrastructure through Nona Biosciences, fostering collaborations with major pharmaceutical companies, and unlocking the full potential of its extensive drug pipeline.

These integrated strategies aim to deliver sustainable innovation and long-term success while enhancing patient treatment options across various therapeutic areas. Harbour BioMed's proprietary antibody discovery platforms are crucial to forming a dense ecosystem of global collaborations, allowing them to accelerate innovative drug development.

Financial Highlights

Harbour BioMed's financial results for 2025 were impressive, showcasing significant growth and profitability. Total revenue reached approximately $158 million, a remarkable 314.6% increase compared to the previous year. This surge can be attributed to enduring strategic alliances with multinational pharmaceutical companies and escalating revenue streams generated by Nona Biosciences.

The company recorded a net profit of around $92 million, representing a shocking 33-fold increase from 2024, a testament to its operational efficiency and effective revenue-driving collaborations. When accounting for adjusted items such as share-based compensation, the year-end adjusted net profit soared to approximately $101 million, marking an 11-fold increase from the prior year. As of December 31, 2025, HBM's cash reserves stood at $403 million, showcasing their strong financial positioning and capacity for future investments.

Collaborations and Expanding Ecosystem

In recent years, Harbour BioMed has significantly enhanced its collaboration efforts with renowned biotechnology innovators and pharmaceutical giants across the globe, solidifying its standing in antibody discovery and biologics development. In 2025 alone, key partnerships were established with industry leaders such as AstraZeneca, Windward Bio, and Pfizer, enhancing their collaborative innovation model.

Notably, the ongoing relationship with AstraZeneca evolved into a multi-target and program collaboration, illustrating HBM's adaptive partnership model. This partnership emphasizes shared strategic initiatives, integrating research and development, equity investments, and the establishment of collaborative innovation labs.

Advancements in Pipeline

HBM's rich pipeline continues to develop various therapeutics aimed at addressing diseases with significant unmet needs. From preclinical to late-stage clinical development, nearly 20 drug candidates span diverse therapeutic spectrums including oncology and immunology. A few key products are positioned for success in the market:

• - Batoclimab (HBM9161): This innovative anti-FcRn monoclonal antibody addresses autoimmune diseases and shows substantial promise as a treatment for generalized myasthenia gravis.
• - HBM9378: A fully human monoclonal antibody targeting TSLP shows potential for treating asthma, with significant clinical trial advancements in 2025.
• - Porustobart (HBM4003): This next-generation anti-CTLA-4 antibody demonstrates innovative properties that may outdo traditional antibody therapies in efficacy and safety.

Looking Forward

As HBM moves into 2026 and beyond, the company aims to accelerate the development of its innovative assets and expand its reach globally. The focus remains on fostering advanced partnerships and driving pipeline advancement to realize the value of its technology platforms and therapeutics.

The introduction of AI-driven methodologies in the antibody discovery process positions Harbour BioMed as a pioneer in finding innovative solutions in the biopharmaceutical landscape. By 2028, they aspire to be recognized as a leading biopharmaceutical platform, manufacturing transformative therapies that significantly improve patient outcomes worldwide.

Conclusion

Harbour BioMed's outstanding performance in 2025 not only reflects its commitment to developing next-generation therapeutics but also highlights the company's strategic foresight and capacity for growth. Empowered by innovative collaborations and a strong pipeline, HBM stands poised to make substantial contributions to the healthcare industry, enhancing the lives of patients globally.